MYOV

Myovant Sciences Ltd. (MYOV) | Rumor.io

Myovant Sciences

MYOV

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about MYOV?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Mar 13

Myovant Sciences Ltd. ($MYOV) has seen significant insider buying, with Japanese chemical company Sumitomo Chemical purchasing $1.39B of shares and Carl Icahn increasing his ownership by 35%.
The company's quarterly revenue growth rate YoY is 84.10%, ranked highly in a database.
Myovant Sciences Ltd. ($MYOV) has multiple analyst price targets, with one target listed for next week.

Generated by AI

Sentiment

Of the messages about MYOV that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.22% +5.78
Bearish	—	—	—	2.78% -5.78

Bullish· Oct 25

Analysts are highly confident in Myovant Sciences, with a 83% buy consensus.
Myovant Sciences has received a sweetened takeover bid from Japanese pharma company Sumitomo, valuing the company at $2.9 billion.
The company's stock price has been increasing, with multiple large trades and a significant volume of shares changing hands.

Bearish· Oct 24

The buyout price of $27 is considered a huge rip-off by some investors.
The acquisition price is seen as a low-ball offer, with some investors feeling that the company was undervalued at $22.75 and therefore the buyout price of $27 is not justified.
The buyout process is perceived as corrupt, with some investors believing that the company's management and Sumi, the acquirer, acted in their own interests and against the interests of minority shareholders.

Generated by AI

Topics

Of the messages about MYOV that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	100%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Earnings· May 11

Myovant Sciences Ltd. (MYOV) Q1 2022 earnings call transcript is available.
No specific details about MYOV's earnings are mentioned in the post.
No other relevant information is provided about MYOV's earnings.

Analysts· Aug 9

SVB Leerink analyst Roanna Ruiz upgraded Myovant Sciences to Outperform from Market Perform with a price target of $23.
Evercore raised its price target for Myovant Sciences to $27.
Analysts are mildly confident about Myovant Sciences, with a buy consensus of 80% among 12 analysts.

Announcements· Nov 16

Myovant Sciences Ltd. has appointed Ann Tomlin as Senior Vice President of Human Resources, effective immediately.
Myovant Sciences has announced new employment inducement grants under NYSE Rule 303A.08, with details to be disclosed in a future filing.
Myovant Sciences has made two key personnel announcements: the appointment of Ann Tomlin as Senior Vice President of Human Resources and the new employment inducement grants.

Technical Analysis· Dec 4

$MYOV has broken its ascending channel, which may indicate a short-term bearish trend, with the stock potentially falling back to $15.
The stock's technicals are strengthening, with a potential breakout above $17.40-$17.50, which could lead to a significant price increase.
$MYOV has formed a cup and handle pattern on its 5-minute chart, with a potential breakout above $17.48, which could lead to a price target of $17.88.

Generated by AI

Community

Of the messages about MYOV, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	98.9%
Newcomers	—	—	0%	1.1%

Regulars· Mar 10

Sumitomo Chemical Co., Ltd. has increased its holding in Myovant Sciences by 889% after acquiring 51,599,200 shares at $27 per share, totaling $1,393,178,400.
Myovant Sciences has requested the NYSE to delist the company from listing and/or registration under Section 12(b) of the Exchange Act, with a notification of removal to be filed with the SEC.
Sumitovant Biopharma has completed its acquisition of Myovant Sciences, with details provided in the company's 8-K filing with the SEC.

Newcomers· Oct 24

The acquisition of Myovant Sciences Ltd. by Sumitomo Pharma is valued at $2.9 billion, with the latter offering $27 per share in cash.
The deal includes the phase 2 in vitro fertilization asset, which contributed to Sumitomo's stock price increase of almost 20% to close the buyout.
The acquisition price of $27 per share is higher than the previously offered price, indicating a sweetened deal for the remaining shareholders of Myovant Sciences Ltd.

Generated by AI

Also Discussed

Investors talking about MYOV also mention

#	Name	Attention
1	Aurinia Pharmaceuticals IncAUPH	0.01%+0.01
2	TG Therapeutics Inc.TGTX	0.01%+0
3	ASLN - ASLAN Pharmaceuticals Limited	——
4	Axsome Therapeutics IncAXSM	0.01%0
5	GTHX - G1 Therapeutics, Inc.	——
6	PDS Biotechnology CorporationPDSB	0%-0.01
7	PRVB - Provention Bio, Inc.	——
8	MRTX - Mirati Therapeutics, Inc.	——
9	ITCI - Intra-Cellular Therapies, Inc.	——
10	NARI - Inari Medical, Inc.	——